8-K: OptimizeRx Reaffirms FY2023 Revenue and EBITDA Estimates, Updates 2024 Revenue Guidance

OptimizeRx reaffirms its prior FY2023 revenue and adjusted EBITDA estimates while updating its 2024 revenue guidance due to a change in accounting treatment.

Summary

• OptimizeRx has provided an update on its financial reporting timeline and reaffirmed its previous revenue and adjusted EBITDA estimates for fiscal year 2023.
• The company is finalizing its year-end audit, which includes the acquisition of Medicx Health and a realignment of its core business lines.
• A material weakness related to internal processes with third-party vendors is also being addressed.
• The company plans to hold an earnings call on March 28, 2024, to discuss its fourth quarter and full-year 2023 results.
• Due to a change in accounting treatment for certain revenue streams from Medicx Health, 2024 revenue guidance is updated to at least $100 million.
• The adjusted EBITDA guidance for 2024 remains unchanged at greater than $11 million.
• Preliminary unaudited estimates for FY2023 indicate revenue exceeding $68-$70 million and adjusted EBITDA in the range of $3-$4 million, consistent with prior guidance.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the change in revenue recognition is a negative, the reaffirmation of FY2023 guidance and strong 2024 EBITDA guidance are positive. The company is also actively addressing a material weakness.

Positives

• The company is reaffirming its previously announced FY2023 revenue and adjusted EBITDA guidance.
• The adjusted EBITDA guidance for 2024 remains strong at greater than $11 million.
• The company is actively addressing a previously disclosed material weakness related to internal processes.

Negatives

• 2024 revenue guidance has been updated to at least $100 million due to a change in accounting treatment, which may be perceived negatively by some investors.
• The company is still working to complete its year-end audit, which includes the acquisition of Medicx Health and a realignment of its core business lines.

Risks

• The preliminary unaudited results are subject to change upon completion of the audit.
• The company's independent auditor has not reviewed the preliminary results and does not express an opinion on them.
• There is a risk that the company or its auditors may identify items that require adjustments to the preliminary estimates.
• The company is working to remediate a previously disclosed material weakness related to internal processes.

Future Outlook

The company anticipates revenue to be at least $100 million for 2024 and adjusted EBITDA to be greater than $11 million. The company is working to complete its year end close and audit processes by the filing deadline for non-accelerated, smaller reporting companies.

Management Comments

• OptimizeRx reaffirms its commitment to maintaining open communication with investors, analysts, and other stakeholders.
• The company looks forward to talking with the investment community at upcoming conferences and during the forthcoming earnings call.

Industry Context

This announcement is relevant to the healthcare technology sector, particularly companies providing solutions to life sciences organizations. The change in revenue recognition method highlights the complexities in accounting for digital health services and the importance of clear financial reporting.

Comparison to Industry Standards

• It is difficult to make a direct comparison without knowing the specific revenue recognition policies of other companies in the healthcare technology sector.
• However, the change from gross to net revenue recognition is not uncommon in the industry, particularly for companies that operate through channel partners.
• Companies like Veeva Systems and IQVIA are larger players in the healthcare technology space, but their business models and revenue streams may differ significantly from OptimizeRx.
• The reaffirmation of EBITDA guidance is a positive sign, suggesting that the underlying profitability of the business remains strong despite the revenue accounting change.

Stakeholder Impact

• Shareholders will be impacted by the updated revenue guidance for 2024.
• Investors will be interested in the details of the accounting change and its impact on future financial results.
• Analysts will be updating their models based on the new information.
• Employees may be impacted by the operational realignment.

Next Steps

• The company will complete its year-end audit.
• The company will hold a conference call on March 28, 2024, to discuss its Q4 and full-year 2023 results.
• The company will continue to communicate with investors and stakeholders.

Key Dates

Keywords

OptimizeRx, OPRX, revenue, EBITDA, financial results, earnings call, Medicx Health, audit, accounting treatment, guidance